The challenge and opportunity of gut microbiota-targeted nanomedicine for colorectal cancer therapy

IF 23.7 Q1 MICROBIOLOGY
iMeta Pub Date : 2024-06-10 DOI:10.1002/imt2.213
Yaohua Wei, Feng Shen, Huidong Song, Ruifang Zhao, Weiyue Feng, Yue Pan, Xiaobo Li, Huanling Yu, Giuseppe Familiari, Michela Relucenti, Michael Aschner, Hanping Shi, Rui Chen, Guangjun Nie, Hanqing Chen
{"title":"The challenge and opportunity of gut microbiota-targeted nanomedicine for colorectal cancer therapy","authors":"Yaohua Wei,&nbsp;Feng Shen,&nbsp;Huidong Song,&nbsp;Ruifang Zhao,&nbsp;Weiyue Feng,&nbsp;Yue Pan,&nbsp;Xiaobo Li,&nbsp;Huanling Yu,&nbsp;Giuseppe Familiari,&nbsp;Michela Relucenti,&nbsp;Michael Aschner,&nbsp;Hanping Shi,&nbsp;Rui Chen,&nbsp;Guangjun Nie,&nbsp;Hanqing Chen","doi":"10.1002/imt2.213","DOIUrl":null,"url":null,"abstract":"<p>The gut microbiota is an integral component of the colorectal cancer (CRC) microenvironment and is intimately associated with CRC initiation, progression, and therapeutic outcomes. We reviewed recent advancements in utilizing nanotechnology for modulating gut microbiota, discussing strategies and the mechanisms underlying their design. For future nanomedicine design, we propose a 5I principle for individualized nanomedicine in CRC management.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":73342,"journal":{"name":"iMeta","volume":null,"pages":null},"PeriodicalIF":23.7000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.213","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iMeta","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imt2.213","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The gut microbiota is an integral component of the colorectal cancer (CRC) microenvironment and is intimately associated with CRC initiation, progression, and therapeutic outcomes. We reviewed recent advancements in utilizing nanotechnology for modulating gut microbiota, discussing strategies and the mechanisms underlying their design. For future nanomedicine design, we propose a 5I principle for individualized nanomedicine in CRC management.

Abstract Image

肠道微生物群靶向纳米药物治疗结直肠癌的挑战与机遇
肠道微生物群是结直肠癌(CRC)微环境不可或缺的组成部分,与 CRC 的发生、发展和治疗效果密切相关。我们回顾了利用纳米技术调节肠道微生物群的最新进展,讨论了相关策略及其设计机制。对于未来的纳米药物设计,我们提出了治疗 CRC 的个性化纳米药物 5I 原则。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
10.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信